Secretome Therapeutics Launches Phase 1 Trial of STM-01 for Dilated Cardiomyopathy
Secretome Therapeutics, a clinical-stage biotech company in Plano, Texas, has initiated a Phase 1 dose-escalation study of its neonatal cardiac progenitor cell therapy, STM‑01, targeting adults with dilated cardiomyopathy (DCM). Additionally, a pediatric DCM trial is planned. Funded by a grant from The Marcus Foundation, the trials will be conducted at Children’s Healthcare of Atlanta under the Marcus Center for Cellular Therapy. Preclinical work showed STM-01 improved cardiac function in both adult and juvenile animal models. The adult trial will first assess safety and tolerability; if successful, it will progress to the pediatric arm.
Secretome Therapeutics Launches Phase 1 Trial of STM-01 for Dilated Cardiomyopathy